199 related articles for article (PubMed ID: 31586296)
1. Unveiling a New Era in Malaria Therapeutics: A Tailored Molecular Approach Towards the Design of Plasmepsin IX Inhibitors.
Munsamy G; Soliman MES
Protein J; 2019 Dec; 38(6):616-627. PubMed ID: 31586296
[TBL] [Abstract][Full Text] [Related]
2. A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy.
Munsamy G; Agoni C; Soliman MES
J Cell Biochem; 2019 May; 120(5):7876-7887. PubMed ID: 30430636
[TBL] [Abstract][Full Text] [Related]
3. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
[TBL] [Abstract][Full Text] [Related]
5. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
6. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
[TBL] [Abstract][Full Text] [Related]
7. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P
Nguyen W; Hodder AN; de Lezongard RB; Czabotar PE; Jarman KE; O'Neill MT; Thompson JK; Jousset Sabroux H; Cowman AF; Boddey JA; Sleebs BE
Eur J Med Chem; 2018 Jun; 154():182-198. PubMed ID: 29800827
[TBL] [Abstract][Full Text] [Related]
9. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in silico studies of naphthoquinones and peptidomimetics toward Plasmodium falciparum plasmepsin V.
Sittikul P; Songtawee N; Kongkathip N; Boonyalai N
Biochimie; 2018 Sep; 152():159-173. PubMed ID: 30103899
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes.
Abiri A
Med Hypotheses; 2018 Sep; 118():68-73. PubMed ID: 30037618
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
Nezami A; Luque I; Kimura T; Kiso Y; Freire E
Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
[TBL] [Abstract][Full Text] [Related]
13. Antimalarial Phytochemicals Identification from
Shah AP; Parmar GR; Sailor GU; Seth AK
Folia Med (Plovdiv); 2019 Dec; 61(4):584-593. PubMed ID: 32337872
[TBL] [Abstract][Full Text] [Related]
14. Modeling and resistant alleles explain the selectivity of antimalarial compound 49c towards apicomplexan aspartyl proteases.
Mukherjee B; Tessaro F; Vahokoski J; Kursula I; Marq JB; Scapozza L; Soldati-Favre D
EMBO J; 2018 Apr; 37(7):. PubMed ID: 29519896
[No Abstract] [Full Text] [Related]
15. New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II.
Dan N; Bhakat S
Eur J Med Chem; 2015 May; 95():324-48. PubMed ID: 25827401
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
[TBL] [Abstract][Full Text] [Related]
17. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
[TBL] [Abstract][Full Text] [Related]
18.
Sharma PP; Kumar S; Kaushik K; Singh A; Singh IK; Grishina M; Pandey KC; Singh P; Potemkin V; Poonam ; Singh G; Rathi B
J Biomol Struct Dyn; 2022 Nov; 40(18):8352-8364. PubMed ID: 33870856
[TBL] [Abstract][Full Text] [Related]
19. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
20. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
